| Ytd | -79.62% | |
| 1y | -60.17% |
| Open | 1.83 | Prev Close | 1.82 | Low | 1.81 | High | 1.85 | Mkt Cap | 123.26M |
| Vol | 291.27K | Avg Vol | 891.32K | EPS | -2.18 | P/E | N/A | Forward P/E | -3.53 |
| Beta | -0.76 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-14 | 50-d Avg | 1.81 | 200-d Avg | 5.80 | 1yr Est | 27.00 |
ENGN News
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-mus
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Inv
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weig
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) w
Recent Corporate UpdatesReduction in Force and Executive Departures: In June 2026, enGene implemente
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigat
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in H
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEN
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash pric
Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperfo
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equ
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) w
Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweigh
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims o
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US
US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech secto
WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) wit
Name change reflects transition towards potential commercial organization in 2027Planned Biologics L
Oppenheimer analyst Leland Gershell maintains enGene Holdings (NASDAQ:ENGN) with a Outperform and
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.44) per share which beat the analyst
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analys
enGene one of nine companies awarded CDRP per yearProgram aims to support CMC development of product
Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and
Oppenheimer analyst Leland Gershell reiterates enGene Holdings (NASDAQ:ENGN) with a Outperform an
UBS analyst Colin Bristow maintains enGene Holdings (NASDAQ:ENGN) with a Neutral and raises the p
Citizens analyst Silvan Tuerkcan maintains enGene Holdings (NASDAQ:ENGN) with a Market Outperform
